Compare Medpace Holdings Inc (MEDP) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs VF Corp — how do they compare? Medpace Holdings Inc trades at $601.09 (market cap $16.90B), while VF Corp trades at $14.59 (market cap $5.81B). The key difference: Medpace Holdings Inc is far larger — about 2.9× VF Corp's market cap, and VF Corp pays a 2.44% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | VFC | |
|---|---|---|
Market Cap | $16.90B | $5.81B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $21.55 |
52-Week Low | $393.42 | $12.21 |
Enterprise Value | $16.52B | $10.09B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
VFC trades at $14.90, down 0.6% on the day, near the low end of analyst targets. Technical indicators are bearish, with mixed recent earnings showing a Q4 beat but Q1 and Q2 misses. Revenue has declined from $11.8B in 2022 to $9.5B in 2025, with net losses in 2024 and 2025, though 2026 projects a return to profitability. The company faces brand-specific headwinds, particularly with Vans, while maintaining a reasonable P/S ratio of 0.62.
The outlook is cautious. Deleveraging progress and a raised 2027 revenue outlook offer some optimism, but persistent Vans weakness and macro pressures pose significant risks. Analyst consensus is Hold, with a $17.44 price target suggesting limited upside from current levels amid ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
